Return to homepagePandemic Pact

Direct comparison of sensitivity and specificity of different molecular diagnostic assays for SARS-CoV-2 available on the WHO website

Grant number: unknown

Grant search

Key facts

  • Disease

    COVID-19

  • start year

    -99

  • Known Financial Commitments (USD)

    $0

  • Funder

    University of São Paulo

  • Principal Investigator

    Angelica Cristine and Ana Paula and Edison Luiz and Luiz Gustavo and Marielton and Paola and Paolo de Almeida Campos and Pessoa and Durigon and Bentim Góes and dos Passos Cunha and Minoprio and Zanotto

  • Research Location

    Brazil

  • Lead Research Institution

    N/A

  • Research Priority Alignment

    N/A

  • Research Category

    Pathogen: natural history, transmission and diagnostics

  • Research Subcategory

    Diagnostics

  • Special Interest Tags

    N/A

  • Study Type

    Unspecified

  • Clinical Trial Details

    N/A

  • Broad Policy Alignment

    Pending

  • Age Group

    Not Applicable

  • Vulnerable Population

    Not applicable

  • Occupations of Interest

    Not applicable

Abstract

The World Health Organization (WHO) makes available on its website six different molecular diagnostic assays for SARS-CoV-2. These assays have been developed and tested in different laboratories and Universities such as the Institute of Virology, Berlin CHARITÉ Faculty of Medicine, University of Hong Kong/IP, Chinese Government Center for Disease Control and Prevention (CDC-China), Control Center and Disease Prevention of the North American Government (CDC-USA), National Institute of Infectious Diseases of Japan and Ministry of Public Health of the Government of Thailand. The assays target different regions of the viral genome such as ORF1ab, Envelope, Nucleocapsid and viral Spike gene. Comparative studies regarding the sensitivity and specificity of these methods have not been developed so far. Using clinical and culture samples of SARS-CoV-2, we intend to carry out a direct comparison of these molecular methods, thus allowing the choice of specific and more sensitive assays for circulating isolates and national territory, and changes in the diagnostic capacity of isolates from different epidemiological stages of the SARS-CoV-2 pandemic. Angelica Cristine de Almeida Campos, Ana Paula Pessoa, Edison Luiz Durigon, Luiz Gustavo Bentim Góes, Marielton dos Passos Cunha, Paola Minoprio, Paolo Zanotto. Pasteur-USP Scientific Platform. Using clinical and culture samples of SARS-CoV-2, we intend to carry out a direct comparison of these molecular methods, thus allowing the choice of specific and more sensitive assays for circulating isolates and national territory, and changes in the diagnostic capacity of isolates from different epidemiological stages of the SARS-CoV-2 pandemic